安杰思: 北京德恒（杭州）律师事务所关于杭州安杰思医学科技股份有限公司2024年年度股东大会的法律意见

Core Viewpoint - The legal opinion provided by Beijing Deheng (Hangzhou) Law Firm confirms the legality of the 2024 annual general meeting of Hangzhou Anjisi Medical Technology Co., Ltd, ensuring compliance with relevant laws and regulations [1][3][12] Group 1: Meeting Procedures - The annual general meeting is scheduled for May 16, 2025, with proper notification published on the Shanghai Stock Exchange and other designated media [3][4] - The meeting will utilize a combination of on-site and online voting methods, with specific timeframes for both [4][5] - The meeting's procedures for convening and conducting are deemed compliant with the Company Law and other relevant regulations [4][5] Group 2: Attendance and Voting - The record date for shareholder attendance is set for May 12, 2025, with 48 shareholders and their proxies representing 57,830,094 shares, accounting for 71.7701% of the total voting shares [4][5] - The voting results indicate a high level of agreement among shareholders, with significant support from minority investors [6][7][8] Group 3: Voting Results - A total of 18 agenda items were voted on, with the majority receiving overwhelming support, including votes from minority shareholders [5][6][9] - Specific resolutions, such as the election of directors and supervisors, received substantial approval, reflecting strong shareholder confidence [10][11] Group 4: Conclusion - The legal opinion concludes that all aspects of the meeting, including the convening, attendance, and voting procedures, are in accordance with the Company Law and the company's articles of association, rendering the resolutions valid [12]